David Dibardino, MD
Critical Care Medicine · Philadelphia, PANPI 1003127135
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $42,497 of the $62,632 with a category attached, or 67.9%. 17 manufacturers reported payments, led by Ethicon Endo-surgery Inc. at 33.2% of the total. 2025 is the largest year on record at $17,465, 4.5 times the $3,848 reported in 2019. Among critical care medicine clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 132 payments — averaging $474.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ethicon Endo-surgery Inc.$21K
- Janssen Research & Development, LLC$9K
- Medical Device Business Services, Inc.$6K
- Cook Incorporated$6K
- Intuitive Surgical$5K
- Boston Scientific$5K
- plus $11K from 11 others
Across 61 payments — averaging $33,246 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$1.1M
- Galvanize Therapeutics, Inc$609K
- Johnson & Johnson$136K
- Erbe Elektromedizin GmbH$99K
- Ethicon Endo-surgery Inc.$80K
- Siemens Medical Solutions USA, Inc.$19K
- plus $15K from 1 others
What the payments were for
- Consulting fees$42,49768%
- Speaking & faculty fees$1,6753%
- Travel & lodging$9,74116%
- Food & beverage$3,7046%
- Education$5,0148%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ethicon Endo-surgery Inc. | 17 | $20,812 |
| Janssen Research & Development, LLC | 15 | $8,843 |
| Medical Device Business Services, Inc. | 3 | $6,222 |
| Cook Incorporated | 10 | $6,113 |
| Intuitive Surgical | 13 | $4,767 |
| Boston Scientific | 8 | $4,719 |
| Galvanize Therapeutics, Inc | 16 | $2,633 |
| Johnson & Johnson(2 entities) | 27 | $2,584 |
| Noah Medical Corporation | 2 | $2,250 |
| Olympus Corporation | 3 | $1,643 |
| Pulmonx Corporation | 9 | $828 |
| ERBE USA Inc | 4 | $721 |
| Siemens Medical Solutions USA, Inc. | 1 | $196 |
| AstraZeneca | 1 | $127 |
| Novocure Inc. | 1 | $101 |
| Sanofi | 1 | $43 |
| Pinnacle Biologics, Inc | 1 | $31 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NeuFlex$17,831
- Monarch Platform$8,012
- GENERAL PULMONARY$4,100
- Neuwave$3,029
- ION$3,000
- GALAXY$2,250
- ALIYA SYSTEM$2,200
- Da Vinci Surgical System$958
- CHARTIS CATHETER$722
- ZEPHYR DELIVERY CATHETER$722
- ZEPHYR ENDOBRONCHIAL VALVE$722
- PULMONX CHARTIS TABLET CONSOLE$722
- Erbe VIO CRYO APC$459
- DA VINCI SP$300
- GENERAL - THERAPIES$275
- ERBE$198
- Cios Spin$196
- OPTUNE LUA (NOVOTTF-200T)$101
How this compares
$62,632 in reported general payments places this provider in the 95th percentile of 354 critical care medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 146 | $108,693 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 91 | $42,655 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $6,687 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 106 | $3,388 |
| Arnuity ElliptaFluticasone Furoate | 14 | $2,942 |
| Roflumilast | 42 | $2,669 |
| Azithromycin | 22 | $164 |
| Prednisone | 41 | $111 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBreztri Aerosphere | $127 | $6,68711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 354 critical care medicine providers in Pennsylvania.
Other critical care medicine in Philadelphia
- Harold PalevskyPhiladelphia$55K
- Steven KawutPhiladelphia$34K
- Kerri SmithPhiladelphia$30K
- Michael BeersPhiladelphia$28K
- Daniel DorganPhiladelphia$23K
- Belinda Rivera-LebronPhiladelphia$18K
- Kevin MaPhiladelphia$15K
- Joshua DiamondPhiladelphia$13K
- Gregory TinoPhiladelphia$9K
- Anthony LanfrancoPhiladelphia$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.